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Objective:  To determine outcomes of small renal masses (≤4cm) on active surveillance and explore 
factors which can influence their growth  
Patients and Methods:   226 patients between January 2007 and December 2014 were analyzed using 
cross-linked methodology of healthcare data and independent review.  Cancer specific and non-specific 
survival were the primary outcomes.  Growth kinetics, factors influencing growth and need for 
interventions were secondary outcomes. 
Results: 101 (64.4%) solid and 4 (5.9%) cystic SRMs showed growth. 43 (19.02%) of SRMs required 
treatment interventions.  Seven patients (7/158; 4.4%) died due to renal cancer at a median follow-up of 
21.7 (SD 10.6, min 6-42) months, all in solid category. Independent review of serial radiological imaging 
of these 7 cases showed two patients had subtle metastatic disease at the initial presentation, and 5 of 
the 7 did not adhere to recommended imaging regime.  33 (33/158; 20.8%) died due to other causes 
including non-renal cancers (14/158; 8.8%).  Multivariate analyses showed that lower eGFR at baseline, 
co-morbidities and tumour location were independently associated with growth in size.   
 
Conclusions: A higher cancer-specific mortality was seen in the present study compared to the reported 
literature.  Independent critical review of imaging of cases with poor outcome underscored the 
importance of adherence to a robust protocol including follow up.  Comorbid conditions had a 











Predictors of growth and progression in SRMs on active surveillance remain poorly defined mainly due 
to a dearth of good quality longitudinal observational data (1-4).  The universal healthcare model in the 
National Health Services (NHS) of the United Kingdom has the advantage of studying longitudinal 
observational data, especially through linkage methodology using a common identifier such as unique 
Community Health Care Index (CHI) number.   The universal healthcare cover to a population in a well-
defined geographical area provides an ideal environment to study natural history of diseases such as 
early renal cancer (SRMs), in particular outcomes of continued surveillance.   Electronic patient records 
including demographic, clinical episodes, imaging and histopathology data can easily be linked to answer 
research question.  Third party certification and review by independent body of the data where 
researchers have little influence remains a significant advantage.  One of the key questions in SRMs 
remains cancer-specific and non-cancer specific mortality in patients opting for active surveillance.  
What influences growth of these masses is also not known, in particularly influence of co-morbid 
conditions has not been reported   (5, 6).   Multiple chronic medical ailments are associated with poorer 
outcomes, morbidities of treatment, complications following surgery, poorer quality of life, 
psychological distress, and higher mortality.   This knowledge base should inform the appropriate follow-
up for patients diagnosed with SRMs.  In a large population based cohort in a well-defined geographical 
area we aimed to address the following objectives:  
1. Assess progression and outcomes (cancer specific and overall survival) in both cystic and small 
renal masses.   
2. Explore factors which can influence progression of these masses including impact of co-morbid 









Patients and Materials    
Study cohort 
The TUCAN (Tayside Urological Cancers Network Database) collects routine data from the patient 
population affected by urological cancers in Tayside, Scotland. NHS Tayside serves a population of more 
than 405,721 based on mid-year 2011 population estimates published by the General Register Office for 
Scotland.  Each inhabitant of this area has a 10 digit CHI number and health records can be accessed 
using this common identifier.  Patients were identified from TUCAN Database using validated record 
linkage methodology as described previously (7).  All patients with SRM in this defined population were 
recorded in a database after discussion in multidisciplinary tumours board meetings using an agreed 
data sheet (Supplementary material).   The study had an initial and updated Institutional approval 
(Caldicott/CSAppGN021211; Caldicott/IGTCAL2973).   226 patients who opted for active surveillance for 
SRMs after review at multidisciplinary meetings and face-to-face meetings with an urologist between 
January 2007 and December 2014 were identified and recruited into the study.  158 patients were 
diagnosed with solid SRMs.  68 were identified as cystic masses.   
 
Outcome data   
Patients opting for active surveillance for SRMs were imaged at regular interval (6-12months) using 
CT/MR scans and reviewed in multidisciplinary meetings if reported any change in size.   All imaging data 
and reports were available on CARESTREAM Vue Picture Archiving and Communication System (PACS) 
(http://www.carestream.com/specials/campaign/search-pacs) for review and follow-up.  Similarly clinic 
letters and other communications including re-admissions, blood investigations were available on 
Clinical Portal System of the organization.  There were only a few patients where ultrasound was used 
for follow-up with immediate conversion to CT scan in case of any suspicious of growth or poor 
visualization.  The information was retrieved for a number of demographic variables: age, gender, and 
Scottish Index of Multiple Deprivation (SIMD).  The SIMD is a scoring system utilized by Scottish 
Government to identify areas of deprivation (www.scotland.gov.uk/topics/statistics/SIMD).  The system 
uses a quintile scoring system, which classifies geographical areas as most deprived (1) to least deprived 
(5).   Clinical factors included growth in size, initial presentation (symptomatic versus asymptomatic), 
multiplicity, Charlson index, location of tumour, and baseline eGFR (at least 3 months prior to the 
diagnosis) and most recent eGFR (within last 3 months of most recent scan).     
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Primary outcomes and Interventions 
Primary outcome of the study was cancer-specific and non-cancer specific survival of patients on active 
surveillance.  Secondary outcomes were growth of SRMs.  Cystic SRM growth was defined as an increase 
in cyst complexity and migration of a class to a higher level and was determined by the uro-radiologist 
mainly based on changes in the wall or septal enhancement, increased nodularity, or calcifications over 
a time period on follow-up scans.  Tumour growth of solid SRM was defined as any increase in the 
maximum axial dimensional size (two axial measurements perpendicular to each other) found on scans 
over a time period.  All SRMs were reviewed in multidisciplinary tumour meetings at the time of initial 
diagnosis and on follow-up, if there was increase in growth.   
Surgical excision/interventions were offered for solid SRMs more than 4 cm in size, those opting for 
change in surveillance protocol following increase in size on imaging (but still less than 4cm) and in 
younger patients with reluctance to follow-up.  Similarly, surgical intervention was offered in cystic 
masses classified following MDT review for bosniak III or IV and follow-up for Bosniak IIF (see Figure 1 
for TASC management algorithm, supplementary files).  The type of surgical procedure, pathological 
outcome including benign or malignant, presence of metastases and progression, and cause of death 
was recorded as an indicator of outcome.     
Independent review of records and imaging data 
Patients developing metastases were reviewed in multidisciplinary meetings (radiologist, urologists, 
pathologist and renal oncologist) and their record linkage was reviewed by at least two experienced 
researchers to ascertain the clinical events.   Cancer-specific deaths were reviewed by an independent 
radiologist not involved in the initial meetings using serial images.  Any subtle metastatic lesion on initial 
or follow-up scans were recorded.  Radiological evidence of these events is available on patient Picture 
Archiving and Communication System (PACS) maintained by NHS Scotland as part of commitment to 
data transparency and sharing (http://www.nisg.scot.nhs.uk/currently-supporting/pacs-and-ris). Death 
certificates review and cause of death was provided by an independent third party (CS, contribution 







Data were double-entered in to SPSS version 21.0.  Preliminary analyses were performed to ensure no 
violation of the assumptions of normality, linearity and homoscedasticity.    Cox proportional hazard 
model was used to assess the relationship between prognostic variables and tumour growth.  Finally, 
cancer specific and overall survival were estimated using Kaplan-Meier analysis in particular exploring 


























The clinical and demographic characteristics are detailed in Table 1.  Statistically significant differences 
were observed in gender, progression of mass size and multiplicity between the cystic and the solid SRM 
groups.  Interestingly, cystic masses were less common in women, showed less progression and tended 
to be multiple when compared to solid masses.   The initial presentation for the majority of patients was 
incidental 46 (74.2%) in the cystic and 113 (78.4%) in the solid SRM groups.  One-hundred-and-one 
(64.4%) solid SRM and four (5.9%) cystic SRM showed growth, and 7 (7/158; 4.4%) metastasized during 
the follow-up.  The mean growth rate from initial scan to final scan was 0.57cm (SD 0.97cm, range 0.2 to 
7.0 cm) with a median of 0.2 cm.  The average growth rate per annum was mean .29 cm/year (SD .48 
cm, min 0 cm and max 3.5 cm) with a median of .1 cm.   A retrospective independent clinical and 
radiological review showed that two patients had subtle undiagnosed metastases at presentation which 
were not identified even at MDT board meetings (Figure 2 for illustrative examples, in supplementary 
files). The follow-up of the 7 (4.4%) patients (all solid masses) who developed metastases during follow-
up is detailed in Table 2.  In three patients, we observed undiagnosed progression of disease on renal 
ultrasound imaging alone (see Figure 3, in supplementary files).  Two patients developed metastasis 
within 3 months of diagnosis and a case could be argued that they had metastatic disease at the time of 
detection, however radiology review did not confirm this.   Moreover, only 2 of the 7 patients who 
developed metastatic disease adhered to our recommended follow-up imaging regime. 
 
The number of patients with observed growth in the cystic SRM group were too small and insufficient to 
analyze further, therefore growth of solid SRM was alone identified as the dependent variable for 
further analysis.   The results from the cox proportional hazard analyses χ2(1) = 847.9, p < .000 identified 
that estimated glomerular filtration rate (eGFR) of less than 60/min/1.73m2 at baseline (2.152, 
p<0.048), central tumour location (.559, p=0.024), and presence of con-current co-morbidity (1.142, 
p=0.016) was statistically associated with growth, (Table 3).  The eGFR was considered as dichotomous 
variables as less than or more than 60 and co-morbidities were considered as continuous variable.   
Location of masses was estimated from imaging and in relation to normal parenchyma.  In terms of 
treatment, (16, 10.0%) patients received RFA, (17, 10.6%) partial nephrectomy, (10, 6.3%) radical 
nephrectomy.  Twenty five (25, 15.6%) patients were offered renal tumour biopsy in our cohort.   Based 
upon the available pathology (12 identified benign pathology and excluded from analysis), no clear trend 
or pattern of growth was observed between pathology and baseline eGFR, (Table 4 in supplementary 
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files).  Changes in the maximum axial diameter (cm) based upon baseline scan and follow-up scan for 
each renal lesion for 226 patients is detailed in (Figure 4 in supplementary files).  There does not appear 
to be any significant differences in growth rate between histologically confirmed benign and malignant 
masses.   In total, 42 patients died in this series, 9 deceased (7 developing metastatic disease on follow-
up for active surveillance, 2 who were followed up for clinically localized disease but actually had spread 
at the time of initial diagnosis) due to renal cancer.  Thirty-three patients died from other causes that 
included (9 from cardiovascular disease, 3 respiratory disease, 1 CKD, 1 meningitis, 1 rheumatoid 
disease, 1 blood disorder, 1 vascular dementia, 1 Parkinson disease, 1 diabetes mellitus, and 14 from 
other cancers), see (Figure 5) for disease specific survival and overall survival.   Figure 6 shows the 
impact of co-morbid conditions on survival during the follow-up of SRMs and as can be seen, most of 



















Tayside Active Surveillance Cohort (TASC) is a longitudinally established group of patients with SRMs 
drawn from a large stable population of more than 400,000.  We have published initial reports (7) and 
this is a further update.  SRMs growth was associated with baseline eGFR, tumour location and co-
morbidity.  It is well-established that chronic renal failure is associated with four to five times increased 
risk of development of cancers in native kidneys (8, 9).  Moreover, lower eGFR is associated with high 
mortality from cancers (10).  Renal function in the elderly may change over time in particular due to 
many factors such as drug use, and other co-morbid conditions and certainly could have implications for 
patients on active surveillance for SRMs.  The vast majority of the SRMs in this series were identified 
incidentally, occasionally at a time when patients may have been hospitalized due to an acute condition 
or other co-morbidity that may have caused reduced renal function at that time during baseline follow-
up.  However, we observed that the distribution of eGFR remained fairly stable over follow-up.  Co-
morbid conditions could also influence growth as observed in the present study.  Hofman and colleagues 
have identified that patients with hypertension and diabetes tended to have a worse renal cell 
carcinoma prognosis due to progression, and this relationship was more prominent in the African black 
ethnic group (11).  Finally, we observed that central tumour location significantly predicted tumour 
growth and this has been identified elsewhere. Specifically, reports have suggested that the risk of 
malignancy is 3.5 times higher for centrally located tumours (12).  Progression to metastatic disease in 
much higher in our series, 7 patients (4.4%), higher than what has been reported in the literature to 
date (1, 13-16).  
Findings of the present study add to the reported literature, in particular to the Delayed Intervention 
and Surveillance for Small Renal Masses  (DISSRM) study as they documented a decline in renal function 
for patients on active surveillance (1, 16).  The decline could be attributed to tumour itself and 
potentially affect growth of these masses.  Pending further research in this area, we cannot rule out the 
possibility that even benign tumour growth is being influenced by low baseline eGFR in our data as 
majority of masses did not have histological confirmation - a situation similar to the DISSRM study.  This 
hypothesis generating observation would certainly benefit from further research.   
Previous studies (17-19) showed a higher mortality in elderly patients’ with SRMs not necessarily due to 
renal cancer.  In the present study, most of patients with more than one co-morbid conditions on active 
surveillance died within or around the first three years of follow-up and this may guide future research 
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and decision making.   Although, cancer specific mortality was higher in our cohort, non-cancer mortality 
still remained a predominant factor in the present study.  There was a strong correlation between 
number of co-morbid conditions and overall survival as seen in Figure 5.   In most decision making 
policies, performance status of patients is taken into consideration (20) however, our data suggests that 
a measure of morbidity should also be recorded and taken into consideration.   
There are a number of differences between our findings and data reported from the United States and 
Canada.  Our growth rate is higher and this could be attributed to the differences in the way growth has 
been defined between the studies.  We considered any increase in size (confirmed in multidisciplinary 
team meetings and reviewed by experienced uro-radiologists) as growth whereas increase above a 
certain limit or doubling time was reported as growth in the previous studies (1, 16).  Most common 
criteria used for growth of SRMs is increase in anatomic tumour size on radiological imaging and this has 
own its limitations, clearly influenced by quality of imaging, imaging protocols, objectivity of observer 
including errors in measurement (21).  There is urgent need for consensus on agreed protocols on 
baseline and follow-up imaging protocols in SRMs on active surveillance. 
 
The main trigger for intervention is believed to be growth rate, but to date there is a lack of robust 
evidence to clearly define what are the growth rate parameters to trigger intervention, as benign 
tumors can display similar growth rates to malignant masses, which inevitably can result in over and 
unnecessary treatment.  Studies have confirmed that biopsy proven RCC and benign tumors displayed 
similar growth rates (22), hence size alone as a marker of aggressiveness and growth becomes 
questionable.   Secondly, in the present study, a higher percentage (>35%) of solid renal masses showed 
zero growth which is more than reported (10% in Johns Hopkins report), and we also observed some 
masses decreased in size.    
 
Ours is the first study to conduct an independent retrospective clinical and radiological review of all the 
patients who showed progression and developed metastatic disease (15, 23, 24).  Two patients in our 
series and one in Canadian series progressed at 3 and 5 months of diagnosis respectively suggesting 
many possibilities including missing of subtle metastatic disease at the time of detection.  This prompted 
our review and in fact two of our cases were clearly seen to have subtle (one in lung and other in liver) 
lesions which progressed on follow-up radiological imaging.  It is important to carefully scrutinize SRM 
patients opting for active surveillance for subtle metastatic lesions (see Figure 1) at the time of 
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diagnosis.  None of the studies on this subject has used an independent review of imaging and our 
observation and experience clearly makes a case for it.  In contrast to DISSRM data (16) and Canadian 
report (25) where the rate of metastatic progression was thought to be low <2%, rate of progression to 
metastatic disease in the present study is 4.4%.  One explanation to account for the higher rate of 
patients who developed metastasis in our series, is that 5 of the 7 patients did not adhered to 
recommended follow-up imaging regime.  This observation might well explain the increased rates of 
metastasis.  Adherence to imaging protocols through CT or MRI imaging modality is important as this 
may affect patient outcomes.   
 
It is our experience that the use of ultrasound imaging is sub-optimal to safely assess tumor growth on 
surveillance.  The cost and burden of serial imaging is significant, and there is conflicting reports 
regarding the risk of secondary malignancy (26-28). No recommendations or guidelines exist for imaging 
modality and timing of surveillance but it is evident from our observation that US imaging is not safe to 
detect renal cancer progression.  This may be due to operator dependence in nature using this imaging 
modality.    
 
Despite its merits, the current study is not devoid of limitations. Firstly, some data has been collected 
retrospectively and this is a single institutional series, therefore, the results should be replicated with a 
multi-institutional larger sample.  As is true for cohort studies in general, data collection in population-
based studies relies on robust linkage with available databases (e.g., hospital records, death certificates, 
etc) and we have demonstrated a methodology in ascertaining validity of this approach in the past 
(Ganeswaren prostate biopsy and a recent biopsy study).  Moreover, using a unique identifier for a 
stable population in a well-defined geographical area provided us a good opportunity to assess various 
factors which can potentially contribute to the growth of small renal masses.  Secondly, there may be 
debate on the manner of determining presumed tumor growth rates. The calculated presumed growth 
rates may represent an underestimation of tumor growth as the exact time and growth pattern is 
unknown.  Additionally, observed growth rates are likely biased by only including tumors undergoing 12 
months of observation, as tumors demonstrating rapid growth would be more likely to undergo 
definitive treatment.  There is also the possibility that subtle growth changes might have been missed 
when combining the utility of CT and ultrasonography over time.   Thirdly, not all the patients had 
histological characterization right at the beginning of recruitment into this study.  There is a possibility of 
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some benign masses growing during the observation period or some malignant lesions with low growth 
potential showing no growth.    
 
Conclusions 
A higher cancer-specific mortality was seen in the present study compared to the reported literature.  
Independent critical review of imaging of cases with poor outcome underscored the importance of 
adherence to a robust protocol including follow up.  Comorbid conditions had a significant impact on 
growth and overall survival of patients and this should be taken into account while decision making as a 
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